Heights Capital Management’s Ernexa Therapeutics Warrants ERNAW Stock Holding History

Heights Capital Management’s Portfolio ERNAW Stock Details ERNAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.5K	Hold	400,000	–	–	0.01%	239
2026 Q1	$16K	Buy	+400,000	New	+$23.7K	﹤0.01%	219

Other funds holding ERNAW

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Heights Capital Management's ERNAW Position: Q2 2026 in Review

Heights Capital Management held its Ernexa Therapeutics Warrants (ERNAW) position steady in Q2 2026 at 400,000 shares worth $28.5K. The position accounts for 0.01% of the portfolio, ranked #239.

Heights Capital Management first reported a position in ERNAW in Q1 2026 and has held it in 2 quarters since. 6 funds tracked by Wall St. Rank hold ERNAW as of Q2 2026.

Heights Capital Management held 400,000 shares of Ernexa Therapeutics Warrants worth $28.5K as of Q2 2026.
Heights Capital Management left its Ernexa Therapeutics Warrants share count unchanged in Q2 2026.
Ernexa Therapeutics Warrants made up 0.01% of Heights Capital Management's portfolio in Q2 2026, its #239 holding.
Heights Capital Management first reported a position in Ernexa Therapeutics Warrants in Q1 2026 and has held it in 2 quarters since.
6 funds tracked by Wall St. Rank held Ernexa Therapeutics Warrants as of Q2 2026.

Based on Heights Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.